Analysts Set Axon Enterprise, Inc. (NASDAQ:AXON) Target Price at $365.38

Shares of Axon Enterprise, Inc. (NASDAQ:AXON) have been given a consensus recommendation of “Moderate Buy” by the fourteen ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 12-month price target among analysts that have covered the stock in the last year is $365.38.

A number of equities analysts have weighed in on AXON shares. Craig Hallum upped their price target on shares of Axon Enterprise from $370.00 to $376.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Jefferies Financial Group started coverage on Axon Enterprise in a research note on Wednesday, July 17th. They issued a “buy” rating and a $385.00 price target for the company. Bank of America assumed coverage on Axon Enterprise in a report on Wednesday, July 17th. They set a “buy” rating and a $380.00 price target on the stock. Northland Securities increased their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Finally, Barclays lifted their target price on Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th.

Axon Enterprise Trading Up 0.5 %

Shares of AXON stock opened at $395.34 on Friday. Axon Enterprise has a 1 year low of $190.01 and a 1 year high of $398.74. The firm has a fifty day moving average price of $356.27 and a 200-day moving average price of $320.06. The company has a market cap of $29.88 billion, a price-to-earnings ratio of 115.60, a PEG ratio of 10.55 and a beta of 0.94. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. During the same quarter in the prior year, the business posted $0.80 earnings per share. The business’s quarterly revenue was up 34.5% on a year-over-year basis. As a group, equities analysts predict that Axon Enterprise will post 1.79 earnings per share for the current year.

Insider Transactions at Axon Enterprise

In related news, Director Michael Garnreiter sold 1,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $380.99, for a total transaction of $380,990.00. Following the transaction, the director now directly owns 27,259 shares in the company, valued at approximately $10,385,406.41. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Brittany Bagley sold 4,338 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $378.95, for a total transaction of $1,643,885.10. Following the completion of the sale, the chief financial officer now directly owns 98,825 shares of the company’s stock, valued at approximately $37,449,733.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Michael Garnreiter sold 1,000 shares of the company’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $380.99, for a total value of $380,990.00. Following the completion of the transaction, the director now directly owns 27,259 shares in the company, valued at approximately $10,385,406.41. The disclosure for this sale can be found here. In the last quarter, insiders sold 317,981 shares of company stock worth $115,662,734. 6.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Axon Enterprise

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in shares of Axon Enterprise by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock valued at $2,547,878,000 after purchasing an additional 212,401 shares in the last quarter. Sands Capital Management LLC lifted its stake in shares of Axon Enterprise by 0.6% during the fourth quarter. Sands Capital Management LLC now owns 2,628,652 shares of the biotechnology company’s stock worth $679,060,000 after buying an additional 16,347 shares during the period. Motley Fool Asset Management LLC grew its stake in Axon Enterprise by 238.7% during the 1st quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock valued at $153,981,000 after purchasing an additional 346,838 shares during the last quarter. 1832 Asset Management L.P. increased its holdings in Axon Enterprise by 44.0% in the 2nd quarter. 1832 Asset Management L.P. now owns 375,700 shares of the biotechnology company’s stock worth $110,546,000 after buying an additional 114,800 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its stake in shares of Axon Enterprise by 13.9% in the second quarter. Allspring Global Investments Holdings LLC now owns 368,732 shares of the biotechnology company’s stock worth $108,496,000 after acquiring an additional 45,049 shares during the period. 79.08% of the stock is currently owned by institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.